Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML.

Wang L, Jia B, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Naik S, Khawaja MR, Sivik J, Han J, Hohl RJ, Zheng H.

Oncoimmunology. 2018 Jul 11;7(9):e1469594. doi: 10.1080/2162402X.2018.1469594. eCollection 2018.

2.

Therapeutic effect of Northern Labrador tea extracts for acute myeloid leukemia.

McGill CM, Tomco PL, Ondrasik RM, Belknap KC, Dwyer GK, Quinlan DJ, Kircher TA, Andam CP, Brown TJ, Claxton DF, Barth BM.

Phytother Res. 2018 Aug;32(8):1636-1641. doi: 10.1002/ptr.6091. Epub 2018 Apr 27.

PMID:
29701283
3.

Therapeutic Effect of Blueberry Extracts for Acute Myeloid Leukemia.

McGill CM, Brown TJ, Cheng YY, Fisher LN, Shanmugavelandy SS, Gustafson SJ, Dunlap KL, Lila MA, Kester M, Toran PT, Claxton DF, Barth BM.

Int J Biopharm Sci. 2018 Jan;1(1). pii: 102. Epub 2018 Jan 2.

4.

Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients.

Jia B, Wang L, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Rizvi S, Shike H, Bayerl M, Schell TD, Hohl RJ, Zheng H.

Blood Cancer J. 2018 Mar 21;8(3):34. doi: 10.1038/s41408-018-0069-4. No abstract available.

5.

Characteristics of early acute respiratory distress syndrome in newly diagnosed acute myeloid leukemia.

Van de Louw A, Desai RJ, Zhu J, Claxton DF.

Leuk Lymphoma. 2018 Feb 12:1-8. doi: 10.1080/10428194.2018.1435874. [Epub ahead of print]

PMID:
29431568
6.

Orbital Epstein-Barr Virus-Positive Polymorphic B-Cell Lymphoproliferative Disorder in an Apparently Immunocompetent Woman.

Abendroth MD, Bayerl MG, Wilkinson MJ, Claxton DF, Specht CS.

Ocul Oncol Pathol. 2017 Dec;4(1):61-65. doi: 10.1159/000478747. Epub 2017 Aug 11.

PMID:
29344502
7.

STAT3 mediates C6-ceramide-induced cell death in chronic lymphocytic leukemia.

Doshi UA, Shaw J, Fox TE, Claxton DF, Loughran TP, Kester M.

Signal Transduct Target Ther. 2017 Oct 27;2:17051. doi: 10.1038/sigtrans.2017.51. eCollection 2017.

8.

Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.

Prabhu VV, Talekar MK, Lulla AR, Kline CLB, Zhou L, Hall J, Van den Heuvel APJ, Dicker DT, Babar J, Grupp SA, Garnett MJ, McDermott U, Benes CH, Pu JJ, Claxton DF, Khan N, Oster W, Allen JE, El-Deiry WS.

Cell Cycle. 2018;17(4):468-478. doi: 10.1080/15384101.2017.1403689. Epub 2018 Feb 19.

PMID:
29157092
9.

SKI-178: A Multitargeted Inhibitor of Sphingosine Kinase and Microtubule Dynamics Demonstrating Therapeutic Efficacy in Acute Myeloid Leukemia Models.

Hengst JA, Dick TE, Sharma A, Doi K, Hegde S, Tan SF, Geffert LM, Fox TE, Sharma AK, Desai D, Amin S, Kester M, Loughran TP, Paulson RF, Claxton DF, Wang HG, Yun JK.

Cancer Transl Med. 2017 Jul-Aug;3(4):109-121. doi: 10.4103/ctm.ctm_7_17. Epub 2017 Aug 14.

10.

Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia.

Zhu L, Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Palmisiano ND, Wang M, Jia B, Bayerl M, Schell TD, Hohl RJ, Zeng H, Zheng H.

J Hematol Oncol. 2017 Jun 19;10(1):124. doi: 10.1186/s13045-017-0486-z.

11.

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C.

Ann Oncol. 2017 May 1;28(5):1050-1056. doi: 10.1093/annonc/mdx031.

PMID:
28453705
12.

Genome-wide mapping of histone H3K9me2 in acute myeloid leukemia reveals large chromosomal domains associated with massive gene silencing and sites of genome instability.

Salzberg AC, Harris-Becker A, Popova EY, Keasey N, Loughran TP, Claxton DF, Grigoryev SA.

PLoS One. 2017 Mar 16;12(3):e0173723. doi: 10.1371/journal.pone.0173723. eCollection 2017.

13.

PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features.

Teye EK, Sido A, Xin P, Finnberg NK, Gokare P, Kawasawa YI, Salzberg AC, Shimko S, Bayerl M, Ehmann WC, Claxton DF, Rybka WB, Drabick JJ, Wang HG, Abraham T, El-Deiry WS, Brodsky RA, J Hohl R, Pu JJ.

Oncotarget. 2017 May 2;8(18):29887-29905. doi: 10.18632/oncotarget.15136.

14.

Therapeutic inhibition of BCL-2 and related family members.

Levy MA, Claxton DF.

Expert Opin Investig Drugs. 2017 Mar;26(3):293-301. doi: 10.1080/13543784.2017.1290078. Epub 2017 Feb 9. Review.

PMID:
28161988
15.

Chest radiographic and CT findings in hyperleukocytic acute myeloid leukemia: A retrospective cohort study of 73 patients.

Stefanski M, Jamis-Dow C, Bayerl M, Desai RJ, Claxton DF, Van de Louw A.

Medicine (Baltimore). 2016 Nov;95(44):e5285.

16.

Acid ceramidase is upregulated in AML and represents a novel therapeutic target.

Tan SF, Liu X, Fox TE, Barth BM, Sharma A, Turner SD, Awwad A, Dewey A, Doi K, Spitzer B, Shah MV, Morad SA, Desai D, Amin S, Zhu J, Liao J, Yun J, Kester M, Claxton DF, Wang HG, Cabot MC, Schuchman EH, Levine RL, Feith DJ, Loughran TP Jr.

Oncotarget. 2016 Dec 13;7(50):83208-83222. doi: 10.18632/oncotarget.13079.

17.

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.

Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM.

Blood. 2016 Nov 3;128(18):2199-2205. Epub 2016 Sep 6.

18.

Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse model.

Liu Q, Chen L, Atkinson JM, Claxton DF, Wang HG.

Cell Death Dis. 2016 Sep 8;7(9):e2361. doi: 10.1038/cddis.2016.264.

19.

Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia.

Morad SA, Ryan TE, Neufer PD, Zeczycki TN, Davis TS, MacDougall MR, Fox TE, Tan SF, Feith DJ, Loughran TP Jr, Kester M, Claxton DF, Barth BM, Deering TG, Cabot MC.

J Lipid Res. 2016 Jul;57(7):1231-42. doi: 10.1194/jlr.M067389. Epub 2016 May 2.

20.

T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients.

Kong Y, Zhu L, Schell TD, Zhang J, Claxton DF, Ehmann WC, Rybka WB, George MR, Zeng H, Zheng H.

Clin Cancer Res. 2016 Jun 15;22(12):3057-66. doi: 10.1158/1078-0432.CCR-15-2626. Epub 2016 Jan 13.

21.

Hypoxemia During Extreme Hyperleukocytosis: How Spurious?

Van de Louw A, Desai RJ, Schneider CW, Claxton DF.

Respir Care. 2016 Jan;61(1):8-14. doi: 10.4187/respcare.04196. Epub 2015 Sep 29.

22.

Initial respiratory status in hyperleukocytic acute myeloid leukemia: prognostic significance and effect of leukapheresis.

Van de Louw A, Schneider CW, Desai RJ, Claxton DF.

Leuk Lymphoma. 2016;57(6):1319-26. doi: 10.3109/10428194.2015.1094695. Epub 2015 Oct 13.

PMID:
26374497
23.

Intractable myoclonic seizures in an allogeneic stem cell transplant recipient: A rare case of myoclonic epilepsy.

Robuccio A, Ssentongo P, Sather MD, Claxton DF, Gilliam FG.

Epilepsy Behav Case Rep. 2015 Aug 8;4:48-51. doi: 10.1016/j.ebcr.2015.06.005. eCollection 2015.

24.

PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation.

Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Zhu L, Zeng H, Schell TD, Zheng H.

Blood Cancer J. 2015 Jul 31;5:e330. doi: 10.1038/bcj.2015.58.

25.

Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics.

Morad SA, Tan SF, Feith DJ, Kester M, Claxton DF, Loughran TP Jr, Barth BM, Fox TE, Cabot MC.

Biochim Biophys Acta. 2015 Jul;1851(7):919-28. doi: 10.1016/j.bbalip.2015.03.001. Epub 2015 Mar 10.

26.

Extracts of Devil's club (Oplopanax horridus) exert therapeutic efficacy in experimental models of acute myeloid leukemia.

McGill CM, Alba-Rodriguez EJ, Li S, Benson CJ, Ondrasik RM, Fisher LN, Claxton DF, Barth BM.

Phytother Res. 2014 Sep;28(9):1308-14.

PMID:
25340187
27.

Engraftment of Human Primary Acute Myeloid Leukemia Defined by Integrated Genetic Profiling in NOD/SCID/IL2rγnull Mice for Preclinical Ceramide-Based Therapeutic Evaluation.

Barth BM, Keasey NR, Wang X, Shanmugavelandy SS, Rampal R, Hricik T, Cabot MC, Kester M, Wang HG, Shultz LD, Tallman MS, Levine RL, Loughran TP Jr, Claxton DF.

J Leuk (Los Angel). 2014 Sep;2(3). pii: 146. doi: 10.4172/2329-6917.1000146. Epub 2014 Jul 25.

28.

Phase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemia.

Abbi KK, Rybka W, Ehmann WC, Claxton DF.

Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):41-6. doi: 10.1016/j.clml.2014.06.005. Epub 2014 Jun 11.

PMID:
25085441
29.

Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms.

Bisen A, Claxton DF.

Adv Exp Med Biol. 2013;779:179-96. doi: 10.1007/978-1-4614-6176-0_8. Review.

PMID:
23288640
30.

Calcium phosphosilicate nanoparticles for imaging and photodynamic therapy of cancer.

Tacelosky DM, Creecy AE, Shanmugavelandy SS, Smith JP, Claxton DF, Adair JH, Kester M, Barth BM.

Discov Med. 2012 Apr;13(71):275-85. Review.

31.

Targeted indocyanine-green-loaded calcium phosphosilicate nanoparticles for in vivo photodynamic therapy of leukemia.

Barth BM, I Altinoğlu E, Shanmugavelandy SS, Kaiser JM, Crespo-Gonzalez D, DiVittore NA, McGovern C, Goff TM, Keasey NR, Adair JH, Loughran TP Jr, Claxton DF, Kester M.

ACS Nano. 2011 Jul 26;5(7):5325-37. doi: 10.1021/nn2005766. Epub 2011 Jul 8.

PMID:
21675727
32.

Out foxing bcr-abl.

Claxton DF.

Cancer Biol Ther. 2011 Apr 15;11(8):769-70. Epub 2011 Apr 15. No abstract available.

PMID:
21358259
33.

A non-coding cationic lipid DNA complex produces lasting anti-leukemic effects.

Keasey N, Herse Z, Chang S, Liggitt DH, Lay M, Fairman J, Claxton DF.

Cancer Biol Ther. 2010 Sep 15;10(6):625-31. Epub 2010 Sep 13.

34.

SIRS criteria in prediction of septic shock in hospitalized patients with hematologic malignancies.

Ibrahim S, Claxton DF.

Cancer Biol Ther. 2009 Jun;8(12):1101. No abstract available.

PMID:
19652525
35.

Oral administration of analgesia and anxiolysis for pain associated with bone marrow biopsy.

Talamo G, Liao J, Bayerl MG, Claxton DF, Zangari M.

Support Care Cancer. 2010 Mar;18(3):301-5. doi: 10.1007/s00520-009-0652-0. Epub 2009 May 21.

PMID:
19455356
36.

BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma.

Talamo G, Claxton DF, Dougherty DW, Ehmann CW, Sivik J, Drabick JJ, Rybka W.

Bone Marrow Transplant. 2009 Aug;44(3):157-61. doi: 10.1038/bmt.2008.446. Epub 2009 Feb 9.

PMID:
19204716
37.

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.

O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD.

Blood. 2009 Jan 8;113(2):299-305. doi: 10.1182/blood-2008-02-137943. Epub 2008 Oct 17.

38.

Sirolimus in unmanipulated haploidentical cell transplantation.

von Reyn Cream L, Ehmann WC, Rybka WB, Claxton DF.

Bone Marrow Transplant. 2008 Dec;42(11):765-6. doi: 10.1038/bmt.2008.242. Epub 2008 Aug 11. No abstract available.

PMID:
18695659
39.

Sphingosine kinase 1 protein and mRNA are overexpressed in non-Hodgkin lymphomas and are attractive targets for novel pharmacological interventions.

Bayerl MG, Bruggeman RD, Conroy EJ, Hengst JA, King TS, Jimenez M, Claxton DF, Yun JK.

Leuk Lymphoma. 2008 May;49(5):948-54. doi: 10.1080/10428190801911654.

PMID:
18452097
40.

Immunohistochemical analysis of CBFbeta-SMMHC protein reveals a unique nuclear localization in acute myeloid leukemia with inv(16)(p13q22).

Zhao W, Claxton DF, Medeiros LJ, Lu D, Vadhan-Raj S, Kantarjian HM, Nguyen MH, Bueso-Ramos CE.

Am J Surg Pathol. 2006 Nov;30(11):1436-44.

PMID:
17063086
41.
42.
43.

Therapeutic potential of leukemia-derived dendritic cells: preclinical and clinical progress.

Claxton DF, McMannis J, Champlin R, Choudhury A.

Crit Rev Immunol. 2001;21(1-3):147-55. Review.

PMID:
11642601
44.

Apoptosis. Molecules and mechanisms.

Konopleva M, Zhao S, Xie Z, Segall H, Younes A, Claxton DF, Estrov Z, Kornblau SM, Andreeff M.

Adv Exp Med Biol. 1999;457:217-36. Review.

PMID:
10500797
45.

Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses.

Choudhury BA, Liang JC, Thomas EK, Flores-Romo L, Xie QS, Agusala K, Sutaria S, Sinha I, Champlin RE, Claxton DF.

Blood. 1999 Feb 1;93(3):780-6.

46.

Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: evidence for multiple critical loci.

Liang H, Fairman J, Claxton DF, Nowell PC, Green ED, Nagarajan L.

Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3781-5.

47.

Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer.

Ueno NT, Rondón G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA, Andersson BS, Claxton DF, Gajewski JL, Khouri IF, Körbling M, Mehra RC, Przepiorka D, Rahman Z, Samuels BI, van Besien K, Hortobagyi GN, Champlin RE.

J Clin Oncol. 1998 Mar;16(3):986-93.

PMID:
9508181
48.

Human leukemia-derived dendritic cells: ex-vivo development of specific antileukemic cytotoxicity.

Choudhury A, Toubert A, Sutaria S, Charron D, Champlin RE, Claxton DF.

Crit Rev Immunol. 1998;18(1-2):121-31. Review.

PMID:
9419454
49.
50.

Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia.

Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche KO, Andreeff M, Champlin RE.

Blood. 1997 Feb 15;89(4):1133-42.

Supplemental Content

Loading ...
Support Center